SG Americas Securities LLC Buys New Position in Puma Biotechnology, Inc. (NASDAQ:PBYI)

SG Americas Securities LLC purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,416 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Frazier Life Sciences Management L.P. boosted its holdings in Puma Biotechnology by 8.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after acquiring an additional 246,264 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Puma Biotechnology by 2.0% during the first quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock worth $10,366,000 after purchasing an additional 39,239 shares during the last quarter. Renaissance Technologies LLC grew its position in Puma Biotechnology by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock worth $5,715,000 after purchasing an additional 23,600 shares in the last quarter. Great Point Partners LLC grew its position in Puma Biotechnology by 10.6% in the 2nd quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after buying an additional 366,653 shares during the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Michael Patrick Miller sold 23,358 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $3.49, for a total transaction of $81,519.42. Following the transaction, the director now owns 47,000 shares of the company’s stock, valued at $164,030. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 23.70% of the company’s stock.

Puma Biotechnology Price Performance

PBYI opened at $2.79 on Wednesday. The firm has a market cap of $136.85 million, a P/E ratio of 14.68 and a beta of 1.09. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. Puma Biotechnology, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The firm has a 50-day moving average of $2.61 and a 200 day moving average of $3.42.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to the consensus estimate of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period in the prior year, the firm earned $0.05 EPS. On average, research analysts expect that Puma Biotechnology, Inc. will post 0.25 EPS for the current year.

Wall Street Analyst Weigh In

PBYI has been the topic of a number of research analyst reports. StockNews.com upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 2nd.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.